Thermo Fisher Scientific Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

$TMO
Industrial Machinery/Components
Industrials
Get the next $TMO alert in real time by email
tmo-20250130
0000097745FALSE00000977452025-01-302025-01-300000097745us-gaap:CommonStockMember2025-01-302025-01-300000097745tmo:SeniorNotes0.125Due2025Member2025-01-302025-01-300000097745tmo:SeniorNotes200Due2025Member2025-01-302025-01-300000097745tmo:SeniorNotes3200Due2026Member2025-01-302025-01-300000097745tmo:SeniorNotes1.40Due2026Member2025-01-302025-01-300000097745tmo:A1.45SeniorNotesDue2027Member2025-01-302025-01-300000097745tmo:SeniorNotes175Due2027Member2025-01-302025-01-300000097745tmo:SeniorNotes0.500Due2028Member2025-01-302025-01-300000097745tmo:SeniorNotes1.375Due2028Member2025-01-302025-01-300000097745tmo:SeniorNotes1.95Due2029Member2025-01-302025-01-300000097745tmo:SeniorNotes0.875Due2031Member2025-01-302025-01-300000097745tmo:SeniorNotes2375Due2032Member2025-01-302025-01-300000097745tmo:SeniorNotes3650Due2034Member2025-01-302025-01-300000097745tmo:SeniorNotes2.875Due2037Member2025-01-302025-01-300000097745tmo:SeniorNotes1.500Due2039Member2025-01-302025-01-300000097745tmo:SeniorNotes1.875Due2049Member2025-01-302025-01-30

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 30, 2025

THERMO FISHER SCIENTIFIC INC.
(Exact name of Registrant as specified in its Charter)
Delaware1-800204-2209186
(State or other jurisdiction of incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

168 Third Avenue
Waltham, Massachusetts 02451
(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (781) 622-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
      Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
      Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
      Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
      Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $1.00 par valueTMONew York Stock Exchange
0.125% Notes due 2025TMO 25BNew York Stock Exchange
2.000% Notes due 2025TMO 25New York Stock Exchange
3.200% Notes due 2026TMO 26BNew York Stock Exchange
1.400% Notes due 2026TMO 26ANew York Stock Exchange
1.450% Notes due 2027TMO 27New York Stock Exchange
1.750% Notes due 2027TMO 27BNew York Stock Exchange
0.500% Notes due 2028TMO 28ANew York Stock Exchange
1.375% Notes due 2028TMO 28New York Stock Exchange
1.950% Notes due 2029TMO 29New York Stock Exchange
0.875% Notes due 2031TMO 31New York Stock Exchange
2.375% Notes due 2032TMO 32New York Stock Exchange
3.650% Notes due 2034TMO 34New York Stock Exchange
2.875% Notes due 2037TMO 37New York Stock Exchange
1.500% Notes due 2039TMO 39New York Stock Exchange
1.875% Notes due 2049TMO 49New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).       

Emerging growth company   

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  



Item 2.02    Results of Operations and Financial Condition.

On January 30, 2025, the Registrant announced its financial results for the fiscal quarter and year ended December 31, 2024. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Form 8-K and incorporated herein by reference.

The information contained in this report and exhibits hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 (the "Exchange Act") or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01    Financial Statements and Exhibits.

(d)    Exhibits

99.1 Press Release dated January 30, 2025
104 Cover Page Interactive Data File (embedded within the Inline XBRL document)



2


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
THERMO FISHER SCIENTIFIC INC.
Date:January 30, 2025By:/s/ Joseph R. Holmes
Joseph R. Holmes
Vice President and Chief Accounting Officer

3
Get the next $TMO alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$TMO

DatePrice TargetRatingAnalyst
1/10/2025$630.00Mkt Perform → Outperform
Bernstein
12/23/2024Sector Perform
Scotiabank
10/14/2024Buy
Redburn Atlantic
10/1/2024$680.00Overweight
Stephens
8/28/2024$670.00Overweight
Wells Fargo
6/3/2024$650.00Buy
Jefferies
3/18/2024$620.00Neutral
Citigroup
1/24/2024$475.00 → $555.00Overweight → Equal Weight
Barclays
More analyst ratings

$TMO
Press Releases

Fastest customizable press release news feed in the world

See more
  • Thermo Fisher Scientific Introduces the Vulcan™ Automated Lab to Transform Semiconductor Analysis

    Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher"), the world leader in serving science, today announced the launch of the Thermo Scientific Vulcan™ Automated Lab, a groundbreaking solution designed to drive a new era of process development and control in semiconductor manufacturing. The seamlessly integrated system is designed to enhance productivity, increase yield and reduce operating costs for semiconductor manufacturers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318064982/en/ The rapid evolution and miniaturization of semiconductor technology is leading to unprecedented demand for atomic-scale transmission el

    $TMO
    Industrial Machinery/Components
    Industrials
  • Trian Comments on Solventum's Sale of its Purification & Filtration Business

    NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns ~5% of Solventum Corporation (NYSE:SOLV) ("Solventum" or the "Company") and is the Company's largest active shareholder, commented on Solventum's recently announced sale of its Purification & Filtration business to Thermo Fisher Scientific Inc (NYSE:TMO) ("Thermo Fisher"). Trian issued the following statement: "Trian commends Solventum on the announced sale of its Purification & Filtration business and believes this is an important first step in the Company's value creation journey. We believe that part of what attracted strategic interest at such a high valuation multiple was the di

    $SOLV
    $TMO
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials
  • Solventum Announces Sale of its Purification & Filtration Business to Thermo Fisher Scientific Inc. for $4.1B

    Accelerates Solventum's business transformation and sharpens focus on strategic areas for growth to deliver long-term shareholder valueStrengthens balance sheet with proceeds to be used primarily for debt paydownST. PAUL, Minn., Feb. 25, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today announced it has entered into a definitive agreement to sell its Purification & Filtration1 business to Thermo Fisher Scientific Inc. (NYSE:TMO) ("Thermo Fisher") for $4.1 billion. Solventum expects the transaction to be neutral to 2025 EPS and expects an estimated $3.4 billion in net proceeds, which it intends to use primarily to pay down debt. The transaction is expected to be completed by the end of 2025, s

    $SOLV
    $TMO
    Medical/Dental Instruments
    Health Care
    Industrial Machinery/Components
    Industrials

$TMO
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$TMO
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$TMO
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$TMO
SEC Filings

See more

$TMO
Leadership Updates

Live Leadership Updates

See more
  • GeminiBio Appoints Mike Stella to Board

    Strengthening Board with Industry Veterans Gemini Bioproducts, LLC ("GeminiBio"), a biopharma and advanced therapy raw materials supplier, and a portfolio company of BelHealth Investment Partners, LLC ("BelHealth"), a Fort Lauderdale-based healthcare private equity firm, announced today the appointment of Michael Stella to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250218608576/en/Mike Stella, CEO of Ascend Advanced Therapies, joins the Board at GeminiBio to provide strategic leadership in the fields of cell and gene therapy contract development and manufacturing. (Photo: Business Wire) GeminiBio prov

    $AMGN
    $GSK
    $JNJ
    $MRK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components
  • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

    Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

    $EXAS
    $ILMN
    $LAB
    $ME
    Medical Specialities
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • ViroCell Expands Business Development Team to Support Next Phase of Growth

    Traci Kyes and Makis Sigalas bring extensive industry experience to roles focused on expanding ViroCell's business in the US and Europe Team ViroCell will be attending the Cell & Gene Therapy Meeting on the Mesa, 10-12 October 2023 ViroCell Biologics ("ViroCell" or the "Company"), a specialist contract development and manufacturing organisation ("CDMO") in cell and gene therapy clinical trials, announces the appointment of Traci Kyes as Vice President (VP) of Business Development (US) and Makis Sigalas as Senior Business Development Director (Europe). Focused on driving growth in the US and Europe, respectively, Traci and Makis bring a wealth of business development expertise to ViroCel

    $CTLT
    $TMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Machinery/Components
    Industrials

$TMO
Financials

Live finance-specific insights

See more
  • Thermo Fisher Scientific Increases Quarterly Dividend

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.43 per common share, payable on April 15, 2025, to shareholders of record as of March 14, 2025. This reflects an 10% increase over the previous dividend payment of $0.39. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their

    $TMO
    Industrial Machinery/Components
    Industrials
  • Thermo Fisher Scientific Reports Fourth Quarter and Full Year 2024 Results

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, today reported its financial results for the fourth quarter and full year ended December 31, 2024. Fourth Quarter and Full Year 2024 Highlights Fourth quarter revenue grew 5% to $11.40 billion. Fourth quarter GAAP diluted earnings per share (EPS) grew 14% to $4.78. Fourth quarter adjusted EPS grew 8% to $6.10. Full year revenue was $42.88 billion, flat versus prior year. Full year GAAP diluted earnings per share (EPS) grew 7% to $16.53. Full year adjusted EPS grew 1% to $21.86. Further strengthened our industry leadership throughout the year by advancing our trusted partner status with cu

    $TMO
    Industrial Machinery/Components
    Industrials
  • Thermo Fisher Scientific to Hold Earnings Conference Call on Thursday, January 30, 2025

    Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving science, announced that it will release its financial results for the fourth quarter and full year 2024 before the market opens on Thursday, January 30, 2025, and will hold a conference call on the same day at 8:30 a.m. EST. During the call, the company will discuss its financial performance, as well as future expectations. To listen, call (833) 470-1428 within the U.S. or (404) 975-4839 outside the U.S. The access code is 706921. You may also listen to the call live on the "Investors" section of our website, www.thermofisher.com. The earnings press release and related information can also be found in that section of ou

    $TMO
    Industrial Machinery/Components
    Industrials

$TMO
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more